GLYC Insider Trading
Notice: This stock is marked as potentially delisted. It may not be actively trading.
Insider Ownership Percentage: 8.70%
Insider Buying (Last 12 Months): $0.00
Insider Selling (Last 12 Months): $0.00
GlycoMimetics Share Price & Price History
Current Price: $0.16
Price Change: +0.30 (1.20%)
As of 04/8/2026 12:00 AM ET
GlycoMimetics Insider Trading History
| Transaction Date | Insider Name | Title | Buy/Sell | Number of Shares | Average Share Price | Total Transaction | Shares Held After Transaction | Details |
|---|
| 8/7/2024 | Public Equities L.P. Invus | Major Shareholder | Sell | 614 | $18.00 | $11,052.00 | 65,784 |  |
| 8/5/2024 | Public Equities L.P. Invus | Major Shareholder | Sell | 1,645 | $19.00 | $31,255.00 | 66,956 | |
| 8/1/2024 | Public Equities L.P. Invus | Major Shareholder | Sell | 635 | $22.00 | $13,970.00 | 71,463 | |
| 7/29/2024 | Public Equities L.P. Invus | Major Shareholder | Sell | 3,639 | $24.00 | $87,336.00 | 79,667 | |
| 7/26/2024 | Public Equities L.P. Invus | Major Shareholder | Sell | 2,583 | $24.00 | $61,992.00 | 83,307 | |
| 6/20/2024 | Edwin Rock | Insider | Buy | 1,900 | $25.00 | $47,500.00 | 5,654 | |
GlycoMimetics Institutional Trading History
| Reporting Date | Hedge Fund | Shares Held | Market Value | % of Portfolio | Quarterly Change in Shares | Ownership in Company | Details |
|---|
| 5/14/2025 | Wellington Management Group LLP | 1,370,297 | $0.29M | 0.0% | -3.0% | 2.124% |  |
| 5/8/2025 | Jefferies Financial Group Inc. | 585,000 | $0.12M | 0.0% | +38.0% | 0.907% | |
| 3/24/2025 | Wellington Management Group LLP | 1,413,402 | $0.35M | 0.0% | N/A | 2.191% | |
| 2/27/2025 | Jefferies Financial Group Inc. | 423,777 | $0.11M | 0.0% | N/A | 0.657% | |
| 2/17/2025 | VR Adviser LLC | 3,000,000 | $0.75M | 0.1% | N/A | 4.653% | |
| 2/17/2025 | Jefferies Financial Group Inc. | 423,777 | $0.11M | 0.0% | N/A | 0.657% | |
| 2/17/2025 | Caxton Corp | 203,578 | $51K | 0.3% | N/A | 0.316% | |
| 2/14/2025 | Adage Capital Partners GP L.L.C. | 5,091,231 | $1.27M | 0.0% | N/A | 7.896% | |
| 2/13/2025 | ADAR1 Capital Management LLC | 331,827 | $83K | 0.0% | +626.1% | 0.515% | |
| 2/12/2025 | Wellington Management Group LLP | 1,413,402 | $0.35M | 0.0% | N/A | 2.192% | |
| 8/9/2024 | Renaissance Technologies LLC | 826,851 | $0.23M | 0.0% | +483.5% | 1.283% | |
| 8/6/2024 | Acadian Asset Management LLC | 534,753 | $0.15M | 0.0% | +61.8% | 0.830% | |
| 5/15/2024 | NEA Management Company LLC | 3,835,039 | $11.51M | 0.7% | -19.5% | 5.949% | |
| 5/10/2024 | Acadian Asset Management LLC | 330,526 | $0.99M | 0.0% | -38.9% | 0.513% | |
| 5/10/2024 | Vanguard Group Inc. | 2,761,981 | $8.29M | 0.0% | +14.0% | 4.285% | |
| 2/8/2024 | Advisor OS LLC | 101,000 | $0.24M | 0.0% | N/A | 0.157% | |
| 2/5/2024 | Intellectus Partners LLC | 50,720 | $0.12M | 0.0% | -18.2% | 0.079% | |
| 1/18/2024 | MJP Associates Inc. ADV | 101,000 | $0.24M | 0.1% | N/A | 0.157% | |
| 11/15/2023 | Acuta Capital Partners LLC | 27,500 | $41K | 0.0% | N/A | 0.043% | |
| 11/13/2023 | Acadian Asset Management LLC | 844,051 | $1.27M | 0.0% | -26.6% | 1.311% | |
| 11/13/2023 | Sargent Investment Group LLC | 58,000 | $87K | 0.0% | -46.3% | 0.090% | |
| 10/25/2023 | Intellectus Partners LLC | 61,975 | $93K | 0.0% | -15.7% | 0.096% | |
| 8/7/2023 | Acadian Asset Management LLC | 1,149,656 | $2M | 0.0% | -18.0% | 1.788% | |
| 7/31/2023 | Intellectus Partners LLC | 73,475 | $0.13M | 0.0% | -10.1% | 0.114% | |
| 7/18/2023 | Stratos Wealth Partners LTD. | 33,340 | $58K | 0.0% | -67.5% | 0.052% | |
| 5/11/2023 | Letko Brosseau & Associates Inc. | 45,250 | $57K | 0.0% | N/A | 0.070% | |
| 5/11/2023 | Acadian Asset Management LLC | 1,401,653 | $1.77M | 0.0% | -27.9% | 2.182% | |
| 5/10/2023 | Beirne Wealth Consulting Services LLC | 50,000 | $63K | 0.0% | +25.0% | 0.078% | |
| 5/10/2023 | Connor Clark & Lunn Investment Management Ltd. | 159,001 | $0.20M | 0.0% | +143.5% | 0.247% | |
| 5/5/2023 | Truist Financial Corp | 101,000 | $0.13M | 0.0% | N/A | 0.157% | |
| 5/2/2023 | Sargent Investment Group LLC | 108,000 | $0.14M | 0.0% | N/A | 0.168% | |
| 4/27/2023 | Stratos Wealth Partners LTD. | 102,565 | $0.13M | 0.0% | N/A | 0.160% | |
| 4/26/2023 | Chicago Partners Investment Group LLC | 20,000 | $28K | 0.0% | N/A | 0.031% | |
| 2/15/2023 | Freedom Wealth Alliance LLC | 9,452 | $29K | 0.0% | N/A | 0.018% | |
| 2/10/2023 | NEA Management Company LLC | 8,967,706 | $27.17M | 1.5% | -1.3% | 17.107% | |
| 2/10/2023 | Connor Clark & Lunn Investment Management Ltd. | 65,288 | $0.20M | 0.0% | N/A | 0.125% | |
| 2/8/2023 | Beirne Wealth Consulting Services LLC | 40,000 | $0.12M | 0.1% | N/A | 0.076% | |
| 2/2/2023 | Intellectus Partners LLC | 81,730 | $0.25M | 0.1% | -32.2% | 0.156% | |
| 1/31/2023 | AE Wealth Management LLC | 26,898 | $82K | 0.0% | N/A | 0.051% | |
Data available starting January 2016
GlycoMimetics, Inc., a biotechnology company, focuses on the discovery and development of therapies for cancers and inflammatory diseases in the United States. It develops uproleselan, an E-selectin antagonist, which is used in combination with chemotherapy to treat acute myeloid leukemia (AML), as well as completed phase 3 trial to treat relapsed/refractory AML. The company also develops various other programs, including GMI-1687, an antagonist of E-selectin to treat vaso-occlusive crisis; and GMI-2093, a galectin-3 carbohydrate-binding protein. In addition, its portfolio comprises GMI-1359, which targets e-selectin and a chemokine receptor for the treatment of osteosarcoma. The company has a cooperative research and development agreement with the National Cancer Institute; and a collaboration and license agreement with Apollomics (Hong Kong) Limited for the development and commercialization of uproleselan and GMI-1687. GlycoMimetics, Inc. was incorporated in 2003 and is headquartered in Rockville, Maryland.
Read More on GlycoMimetics
Volume
N/A
Average Volume
29,886 shs
Market Capitalization
$10.13 million
P/E Ratio
N/A
Dividend Yield
N/A
Beta
1.62
Who are the company insiders with the largest holdings of GlycoMimetics?
GlycoMimetics' top insider shareholders include:
- Public Equities LP Invus (Major Shareholder)
- Scott D Sandell (Major Shareholder)
- Edwin Rock (Insider)
- Helen M Thackray (CMO)
- Helen M Thackray (VP)
- Helen M Thackray (SVP)
- Bruce S Johnson (SVP)
- Daniel M Junius (Director)
- John L Magnani (SVP)
- Brian M Hahn (CFO)
Learn More about top insider investors at GlycoMimetics.
GlycoMimetics Active Insiders
